- Home
- SPFI vs MNMD Comparison
SPFI vs MNMD Comparison
Compare SPFI & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- MNMD
- Stock Information
- Founded
- SPFI 1941
- MNMD 2019
- Country
- SPFI United States
- MNMD United States
- Employees
- SPFI N/A
- MNMD N/A
- Industry
- SPFI Major Banks
- MNMD Pharmaceuticals and Biotechnology
- Sector
- SPFI Finance
- MNMD Health Care
- Exchange
- SPFI Nasdaq
- MNMD Nasdaq
- Market Cap
- SPFI 662.8M
- MNMD 709.9M
- IPO Year
- SPFI 2019
- MNMD N/A
- Fundamental
- Price
- SPFI $39.29
- MNMD $9.71
- Analyst Decision
- SPFI Buy
- MNMD Strong Buy
- Analyst Count
- SPFI 3
- MNMD 7
- Target Price
- SPFI $41.67
- MNMD $24.71
- AVG Volume (30 Days)
- SPFI 43.0K
- MNMD 1.1M
- Earning Date
- SPFI 10-22-2025
- MNMD 11-06-2025
- Dividend Yield
- SPFI 1.49%
- MNMD N/A
- EPS Growth
- SPFI 19.09
- MNMD N/A
- EPS
- SPFI 3.20
- MNMD N/A
- Revenue
- SPFI $199,001,000.00
- MNMD N/A
- Revenue This Year
- SPFI $13.41
- MNMD N/A
- Revenue Next Year
- SPFI $6.10
- MNMD N/A
- P/E Ratio
- SPFI $12.61
- MNMD N/A
- Revenue Growth
- SPFI 7.49
- MNMD N/A
- 52 Week Low
- SPFI $30.01
- MNMD $4.70
- 52 Week High
- SPFI $42.38
- MNMD $11.02
- Technical
- Relative Strength Index (RSI)
- SPFI 45.89
- MNMD 54.11
- Support Level
- SPFI $39.40
- MNMD $8.70
- Resistance Level
- SPFI $40.93
- MNMD $9.95
- Average True Range (ATR)
- SPFI 1.02
- MNMD 0.50
- MACD
- SPFI -0.21
- MNMD -0.01
- Stochastic Oscillator
- SPFI 5.76
- MNMD 63.12
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).